FSSAI Files Cases Against Nestlé India Baby Food Line
The Food Safety and Standards Authority of India (FSSAI) has initiated legal action against Nestlé India. Specifically, the regulator flagged marketing practices surrounding three infant nutrition products. FSSAI filed three separate adjudication cases alleging violations of statutory marketing codes and quality standards. However, Nestlé India maintains that all its formulations remain fully compliant with Indian food laws. This regulatory dispute carries substantial clinical and policy significance for pediatric healthcare providers across India.
Regulatory Scrutiny Over Infant Nutrition Products
FSSAI examined promotional content for NAN EXCELLA PRO Stage 1 and LACTOGEN PRO 1 on e-commerce platforms. Consequently, the regulator issued notices highlighting specific promotional declarations. For instance, NAN EXCELLA PRO featured marketing claims regarding "5 HMOs" and "Whey Protein." In addition, LACTOGEN PRO 1 labels claimed that whey protein was "easy to digest." FSSAI determined that these statements violated Regulation 4(2) of the Food Safety and Standards Regulations, 2020. This statutory rule explicitly prohibits promotional claims that increase the saleability of infant formulations. Furthermore, the regulator cited Section 3 of the IMS Act, 1992, which bans formula advertising.
Biotin Deficiency in Follow-Up Formula
Beyond promotional claims, the authority evaluated laboratory samples of a Nestlé follow-up formula. Consequently, testing revealed sub-standard biotin content compared to mandated nutritional standards. A government referral laboratory later re-analyzed the sample and confirmed non-conforming biotin levels. Therefore, FSSAI lodged a separate adjudication case regarding this micronutrient shortfall. In contrast, Nestlé India stated that an expert committee previously approved its product labels. The manufacturer argued that its label statements remain factual and scientifically valid. Nevertheless, the food safety authority insists on strict adherence to national infant feeding statutes.
Clinical Implications for Pediatric Practice
Pediatricians in India hold an ethical and legal duty to protect and promote exclusive breastfeeding. Therefore, clinicians must understand the rigorous statutory boundaries established by the IMS Act. Aggressive commercial promotions can inadvertently mislead vulnerable parents into believing formula equals maternal breast milk. Furthermore, adequate micronutrient composition remains vital when infants require clinical supplementation. Healthcare professionals should continue educating families on optimal infant and young child feeding practices through structured paediatrics speciality courses.
Frequently Asked Questions
Q1: Why did FSSAI take action against Nestlé India?
FSSAI filed adjudication cases over promotional claims on two infant formulas and sub-standard biotin in a follow-up formula.
Q2: What specific laws did the promotional claims contravene?
The marketing claims contravened Regulation 4(2) of the FSS Regulations, 2020, and Section 3 of the IMS Act, 1992.
Q3: What was Nestlé India's formal response to the allegations?
Nestlé India stated that its products are fully compliant, scientifically supported, and backed by prior expert committee label approvals.
References
- ‘Fully compliant’: Nestlé India responds to FSSAI action over infant nutritionproducts - ETHealthworld
- FSSAI moves against Nestlé over baby formula claims and biotin test - The Indian Express
- FSSAI initiates legal action against Nestle India over infant nutrition claims and biotin violation - The Economic Times
